FGF2 and myeloid sarcoma: To the best of our knowledge, we are the first to describe significant differences in circulating levels of FGFb, HGF, VEGF; Eotaxin/CCL11, MCP-1/CCL2 and Rantes/CCL5 discriminating among MS clinical forms.